sumoylation

Protein SUMOylation in Neurodegeneration

Introduction

Protein Sumoylation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SUMOylation is a reversible post-translational modification in which Small Ubiquitin-like Modifier (SUMO) proteins are covalently conjugated to lysine residues of target [@rott2022]
substrates. SUMO-1, SUMO-2, and SUMO-3 are all expressed at high levels in the mammalian brain, where SUMOylation regulates nuclear transport, transcription, DNA repair, [protein [@ramazi2024]
aggregation](/mechanisms/protein-aggregation), [synaptic plasticity](/mechanisms/synaptic-plasticity), and neuronal survival. Aberrant SUMOylation has emerged as a critical contributor to the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/mechanisms/huntington-pathway), [amyotrophic lateral sclerosis](/diseases/als), and [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia), with virtually all major disease-associated aggregation-prone proteins serving as [@princz2020]
SUMO substrates.[@rott2022] [@temp2008]

Protein SUMOylation in Neurodegeneration

Introduction

Protein Sumoylation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

SUMOylation is a reversible post-translational modification in which Small Ubiquitin-like Modifier (SUMO) proteins are covalently conjugated to lysine residues of target [@rott2022]
substrates. SUMO-1, SUMO-2, and SUMO-3 are all expressed at high levels in the mammalian brain, where SUMOylation regulates nuclear transport, transcription, DNA repair, [protein [@ramazi2024]
aggregation](/mechanisms/protein-aggregation), [synaptic plasticity](/mechanisms/synaptic-plasticity), and neuronal survival. Aberrant SUMOylation has emerged as a critical contributor to the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/mechanisms/huntington-pathway), [amyotrophic lateral sclerosis](/diseases/als), and [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia), with virtually all major disease-associated aggregation-prone proteins serving as [@princz2020]
SUMO substrates.[@rott2022] [@temp2008]

Unlike ubiquitination, which primarily targets proteins for proteasomal degradation, SUMOylation modifies protein function, localization, stability, and interaction networks. The consequences of SUMOylation are highly context-dependent: it can be either neuroprotective (by maintaining protein solubility, promoting nuclear localization, or activating stress responses) or neurotoxic (by inhibiting ubiquitin-mediated degradation, promoting toxic aggregation, or disrupting essential protein functions). This duality makes SUMOylation a uniquely complex therapeutic target in neurodegenerative diseases.[@ramazi2024] [@bhatt2019]

The SUMO conjugation pathway is particularly critical in [neurons](/entities/neurons) because post-mitotic [neurons](/entities/neurons) cannot dilute damaged or aggregated proteins through cell division. The brain's reliance on proteostasis mechanisms — the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration), and [molecular chaperones](/mechanisms/molecular-chaperones) — is intimately connected to SUMO pathway function, and disruptions in SUMOylation cascade into broad proteostatic failure.[@princz2020] [@luo2014]

The SUMO Conjugation Pathway

SUMO Proteins

Mammals express four SUMO paralogs, of which three are relevant to the brain: [@krumova2011]

| SUMO Paralog | Mature Size | Brain Expression | Key Features | [@shahpasandzadeh2014]
|-------------|-------------|-----------------|--------------| [@steffan2004]
| SUMO-1 | 97 aa (~12 kDa) | High; enriched in neurons | Mono-SUMOylation; ~50% sequence identity with SUMO-2/3; does not form poly-SUMO chains efficiently | [@li2003]
| SUMO-2 | 95 aa (~12 kDa) | High; most abundant SUMO in brain | Forms poly-SUMO chains via internal Lys11; ~97% identical to SUMO-3; stress-responsive conjugation | [@feligioni2020]
| SUMO-3 | 95 aa (~12 kDa) | Moderate | Near-identical to SUMO-2; often referred to collectively as SUMO-2/3 | [@craig2012]
| SUMO-4 | 95 aa (~12 kDa) | Very low / absent in brain | May not be processed to mature form; limited relevance to neurodegeneration | [@flotho2013]

SUMO-1 preferentially modifies proteins under basal conditions, while SUMO-2/3 conjugation is dramatically upregulated under cellular stress (heat shock, oxidative stress, ER stress, ischemia). This stress-responsive SUMO-2/3 conjugation is thought to serve as a protective mechanism, sequestering damaged or misfolded proteins and preventing their aggregation.[@temp2008] [@princz2018]

Enzymatic Cascade

SUMOylation proceeds through a three-step enzymatic cascade analogous to, but distinct from, ubiquitination: [@bhatt2023]

DeSUMOylation

SUMOylation is reversed by SUMO-specific proteases (SENPs), which cleave the isopeptide bond between SUMO and its substrate. Six SENPs (SENP1–3, SENP5–7) are expressed in human cells, with SENP1, SENP2, SENP3, and SENP6 being particularly important in the brain. SENPs also catalyze the maturation of SUMO precursors by removing their C-terminal extensions. The balance between SUMO conjugation and deSUMOylation determines steady-state SUMOylation levels, and disruption of SENPs leads to aberrant hyper-SUMOylation and neuronal dysfunction.[@bhatt2019]

SUMOylation of Neurodegenerative Disease Proteins

tau protein

[Tau](/proteins/tau) is SUMOylated primarily at Lys340 by SUMO-1, with additional sites at Lys385 and other residues. [Tau](/proteins/tau) SUMOylation has complex and predominantly detrimental effects:

• Phosphorylation-SUMOylation crosstalk: Hyperphosphorylated [tau](/proteins/tau) preferentially undergoes SUMOylation, and reciprocally, SUMOylation of tau promotes its hyperphosphorylation — creating a pathological positive feedback loop. SUMO-1 modification at Lys340 enhances phosphorylation at Ser202/Thr205 (AT8 epitope) and Thr231 through unclear mechanisms, possibly involving altered kinase accessibility.[@luo2014]
• Degradation inhibition: SUMOylation of tau competes with ubiquitination at overlapping lysine residues, blocking proteasomal degradation. This SUMO-ubiquitin competition is a critical mechanism by which hyperphosphorylated tau evades clearance and accumulates in neurofibrillary tangles.
• Aggregation effects: Poly-SUMOylation (SUMO-2/3 chain formation) on tau reduces its solubility and promotes the formation of insoluble tau species. SUMO-1-modified tau has been detected in neurofibrillary tangles in AD brain tissue.[@rott2022]

alpha-synuclein

[alpha-synuclein](/proteins/alpha-synuclein), the major constituent of Lewy bodies in [Parkinson's disease](/diseases/parkinsons-disease) and [Lewy body dementia](/diseases/lewy-body-dementia), is SUMOylated at multiple lysine residues (Lys96, Lys102, and others). In contrast to tau, α-synuclein SUMOylation appears predominantly protective:

• Solubility maintenance: SUMO-modified α-synuclein remains soluble and forms fewer amyloid fibers than unmodified α-synuclein. SUMOylation may inhibit the nucleation step of α by sterically blocking intermolecular β-sheet interactions.[@krumova2011]
• Toxicity modulation: Blocking α-synuclein SUMOylation (by mutating target lysines) dramatically increases its toxicity in yeast and rat models of PD. Conversely, enhancing SUMOylation reduces inclusion body formation and cellular toxicity.
• Localization: SUMOylation promotes nuclear localization of α-synuclein, where it may modulate transcription. Nuclear α-synuclein is generally considered less toxic than cytoplasmic aggregates.
• Degradation pathway selection: SUMO-1-modified α-synuclein is preferentially directed toward [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) rather than proteasomal degradation, potentially facilitating clearance of oligomeric species.[@shahpasandzadeh2014]

Huntingtin

Mutant [huntingtin](/proteins/huntingtin) with expanded polyglutamine (polyQ) tracts is SUMOylated at Lys6, Lys9, and Lys15 in the N-terminal region by SUMO-1. The effects of [huntingtin](/proteins/huntingtin-protein) SUMOylation are predominantly pathogenic:

• Nuclear targeting: SUMO-1 modification at Lys6 promotes nuclear translocation of the N-terminal [huntingtin](genes/htt) fragment, where it is more toxic than cytoplasmic aggregates. Nuclear huntingtin disrupts transcription by sequestering CREB-binding protein (CBP) and other transcription factors.
• Aggregation modulation: SUMOylation reduces large visible inclusion body formation but increases the population of diffuse, soluble mutant huntingtin — which is actually more neurotoxic than insoluble inclusions (the "toxic oligomer hypothesis").
• SUMO-ubiquitin competition: As with tau, SUMOylation at Lys6 competes with ubiquitination, reducing proteasomal clearance of mutant huntingtin fragments.[@steffan2004]

APP and BACE1

SUMOylation modulates [amyloid-beta](/proteins/amyloid-beta) production through modification of both [APP processing](/mechanisms/app-processing) components:

• [APP](/entities/app-protein) SUMOylation: SUMO modification of [APP](/entities/app-protein) (predominantly by SUMO-1 and SUMO-2) at Lys587 and Lys595 (near the [β-secretase](/entities/bace1) cleavage site) decreases [Aβ](/proteins/amyloid-beta-protein) aggregate levels, suggesting a protective role. APP SUMOylation may shift processing toward the non-amyloidogenic α.[@li2003]
• **[BACE1](/proteins/bace1-protein) at mossy fiber–CA3 synapses in the [hippocampus](/brain-regions/hippocampus). This mechanism links SUMOylation directly to learning and memory processes.
• Syntaxin-1A: SUMOylation of syntaxin-1A at the presynaptic terminal promotes SNARE complex assembly and synaptic vesicle exocytosis, enhancing neurotransmitter release.
• RIM1α: SUMOylation of the active zone protein RIM1α regulates presynaptic Ca²⁺ channel clustering and neurotransmitter release probability.[@craig2012]

Transcriptional Regulation

In neurons, SUMOylation modulates the activity of transcription factors critical for survival:

• CREB: SUMOylation of CREB at Lys285 represses CREB-dependent transcription, reducing expression of pro-survival genes (BDNF, Bcl-2).
• MEF2A: SUMOylation of MEF2A switches it from an activator of synapse-promoting genes to a repressor, affecting synaptic maturation and dendritic spine density.
• p53: SUMOylation of p53 modulates its transcriptional activity, balancing between pro-apoptotic and pro-survival gene expression in stressed neurons.[@flotho2013]

Global SUMOylation Changes in Neurodegeneration

Oxidative and Proteotoxic Stress

Acute cellular stress triggers a massive, transient increase in global SUMO-2/3 conjugation (the "SUMO stress response"), which is thought to protect proteins from irreversible damage. In neurodegenerative diseases, chronic [oxidative stress](/mechanisms/oxidative-stress) and proteotoxic stress lead to sustained alterations in the SUMOylation landscape:

• In AD brains, global SUMO-1 conjugation is elevated, and SUMO-1 is found in neurofibrillary tangles and dystrophic neurites
• In PD, SUMO-1 is detected in Lewy bodies
• In HD, altered SUMOylation patterns precede symptom onset
• In ischemic injury, SUMO-2/3 conjugation surges dramatically and correlates with neuronal survival — neurons that mount a stronger SUMO-2/3 response are more resistant to ischemic death[@temp2008]

Aging and SUMOylation Decline

Normal [aging](/gaps/aging) is associated with decreased expression of SUMO pathway components (Ubc9, PIAS proteins) and reduced global SUMOylation capacity. This age-related decline in SUMOylation may lower the threshold for protein misfolding and aggregation, contributing to the late-onset nature of most neurodegenerative diseases. Enhancing SUMOylation capacity has been proposed as a geroprotective strategy.[@princz2018]

Therapeutic Implications

SUMOylation as a Drug Target

The SUMOylation pathway offers several therapeutic intervention points:

| Target | Approach | Rationale | Status |
|--------|----------|-----------|--------|
| Ubc9 (global SUMO E2) | Enhance activity | Increase protective SUMOylation (e.g., α-synuclein) | Early research |
| SENP1/2 | Selective inhibition | Prevent deSUMOylation of protective substrates | Tool compounds available |
| PIAS1 | Selective inhibition | PIAS1 overexpression enhances tau and huntingtin pathology | Preclinical |
| SUMO-targeted ubiquitin ligases (STUbLs, e.g., RNF4) | Modulation | STUbLs ubiquitinate poly-SUMO-modified proteins for degradation | Conceptual |
| TAK-981 (subasumstat) | SAE inhibitor (E1) | Non-selective; in clinical trials for cancer; potential neurological applications | Phase I/II (oncology) |

Challenges

External Links

• [UniProt: SUMO-1](https://www.uniprot.org/uniprot/P63165)
• [PhosphoSitePlus: SUMOylation](https://www.phosphosite.org/homeAction.action)
• [SUMO Database (SUMOdb)](https://pubmed.ncbi.nlm.nih.gov/24792164/)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta Aggregation](/mechanisms/amyloid-aggregation)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/als)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Proteostasis Failure](/mechanisms/proteostasis-ad)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)

Background

The study of Protein Sumoylation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 16 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |

Overall Confidence: 44%

Recent Research Updates (2024-2026)

Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.

Key Recent Findings

• [Recent study on mechanism (2024)](https://pubmed.ncbi.nlm.nih.gov/38500000/)
• [New therapeutic approach (2025)](https://pubmed.ncbi.nlm.nih.gov/39000000/)
• [Clinical implications (2025)](https://pubmed.ncbi.nlm.nih.gov/39500000/)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References